December 5, 2005
MINNEAPOLISBarlív, a barley beta-glucan extract from Cargill Health & Food Technologies, improves metabolic control and blood lipid profile in patients with the metabolic syndrome, according to a clinical trial presented at the 2005 annual scientific sessions of the American Heart Association (AHA).
In a double blind, parallel group format, researchers administered low molecular weight and high molecular weight barley beta-glucan (as ready-to-eat cereal bars and juice formulated with Barlív), twice daily to 155 "generally healthy" adults (76 men and 79 women) with low-density lipoprotein (LDL) cholesterol between 130 and 190 mg/dL. Fasting and postprandial blood samples were collected at baseline and after the test period to test for cardiovascular disease (CVD) biomarkers. According to the results, barley beta-glucan significantly improved multiple CVD risk markers in individuals with metabolic syndrome.
"We believe this new ingredient has unique taste and textural properties that will enable great-tasting food and beverage products," said Bill Rock, product manager for Cargill Health & Food Technologies.
You May Also Like
The ashwagandha root production process: Where tradition meets science – article part threeSep 21, 2023
Former FDA employees weigh in on gov’t shutdownSep 27, 2023
HerbalGram celebrates 40 years of bringing ancient herbal traditions back to life in AmericaSep 27, 2023
New science advances probiotics, milk fats and herbsSep 27, 2023